567517-U
Discovery® HS F5 (5 µm) HPLC Columns
L × I.D. 25 cm × 4.6 mm, HPLC Column
Synonym(s):
Discovery Pentafluorophenyl PFP HPLC Column
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
UNSPSC Code:
41115700
eCl@ss:
32110501
NACRES:
SB.52
L × i.d.:
25 cm × 4.6 mm
Particle size:
5 μm
Matrix active group:
PFP (pentafluorophenyl) phase
Pore size:
120 Å
Matrix:
silica gel, high purity, spherical particle platform, fully porous particle
Product Name
Discovery® HS F5 HPLC Column, 5 μm particle size, L × I.D. 25 cm × 4.6 mm
material
stainless steel column
Quality Segment
agency
suitable for USP L43
product line
Discovery®
feature
endcapped
manufacturer/tradename
Discovery®
packaging
1 ea of
extent of labeling
12% Carbon loading
parameter
≤70 °C temp. range, 400 bar pressure (5801 psi)
technique(s)
HPLC: suitable, LC/MS: suitable
L × I.D.
25 cm × 4.6 mm
surface area
300 m2/g
surface coverage
4 μmol/m2
impurities
<10 ppm metals
matrix
silica gel, high purity, spherical particle platform, fully porous particle
matrix active group
PFP (pentafluorophenyl) phase
particle size
5 μm
pore size
120 Å
operating pH range
2-8
application(s)
food and beverages
separation technique
reversed phase
General description
Guidelines for transferring a C18 method to Discovery® HS F5:
Generally, bases are retained longer on the HS F5 than on a C18. Increasing the organic content of a C18 separation 5 to 10 percent will generally provide similar retention on an HS F5. Results with other compounds are highly variable. However, it is generally true that solutes with log Po/w values less than 2.5 will be retained longer on HS F5 compared to a C18. The degree of difference is highly solute dependent.
Generally, bases are retained longer on the HS F5 than on a C18. Increasing the organic content of a C18 separation 5 to 10 percent will generally provide similar retention on an HS F5. Results with other compounds are highly variable. However, it is generally true that solutes with log Po/w values less than 2.5 will be retained longer on HS F5 compared to a C18. The degree of difference is highly solute dependent.
The Discovery® HS F5 bonded phase provides reversed-phase separations that are distinctly different from C18 columns. However, compounds will generally elute within the same retention time window, making most C18 methods easily transferable.
Application
- Determination of 6-hydroxy-1-methyl-1,2,3,4-tetrahydro-beta-carboline, 5-hydroxytryptamine and 5-hydroxyindole acetic acid in the neonatal rat brains using high performance liquid chromatography-electrochemical detection.: This study highlights the use of the Discovery® HS F5 HPLC Column for the sensitive detection of neuroactive compounds in neonatal rat brain samples, advancing our understanding of neurological development and neurotransmitter dynamics (Mao et al., 2009).
- Advantages of pentafluorophenylpropyl stationary phase over conventional C18 stationary phase--application to analysis of triamcinolone acetonide.: This research showcases the superior performance of the Discovery® HS F5 HPLC Column in analyzing corticosteroid formulations, providing insights that could lead to improved analytical methodologies in pharmaceutical analysis (Havlikova et al., 2008).
- Determination of ephedrine alkaloids in Ephedra natural products using HPLC on a pentafluorophenylpropyl stationary phase.: Utilizes the Discovery® HS F5 HPLC Column for the precise and efficient separation of ephedrine alkaloids, contributing to safer and more effective use of Ephedra in herbal supplements (Pellati and Benvenuti, 2008).
- Fast high-performance liquid chromatography analysis of phenethylamine alkaloids in Citrus natural products on a pentafluorophenylpropyl stationary phase.: Demonstrates the efficiency of the Discovery® HS F5 HPLC Column in the rapid analysis of phenethylamine alkaloids, enhancing the quality control of Citrus-based dietary supplements (Pellati and Benvenuti, 2007).
- High-performance liquid chromatographic method with UV photodiode-array, fluorescence and mass spectrometric detection for simultaneous determination of galantamine and its phase I metabolites in biological samples.: This study uses the Discovery® HS F5 HPLC Column to simultaneously quantify galantamine and its metabolites, aiding in the pharmacokinetic profiling of this Alzheimer′s disease medication (Malakova et al., 2007).
Features and Benefits
- Unique selectivity
- Similar retention to C18 (sometimes requires stronger mobile phase)
- Excellent peak shape
- Stable, low-bleed LC-MS separations
- Scalable separations from 3 to 10μm particle sizes
Legal Information
Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany
Still not finding the right product?
Explore all of our products under Discovery® HS F5 HPLC Column
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.